Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 6/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 4/20 | 0.51 |
| ▸ | ESR1 | P03372 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SHBG | P04278 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1236354 | 0.88 | ESR1 (0.66) | STSHSD17B1ESR1MAPTESR2 | |
| SCHEMBL8030999 | 0.88 | ESR1 (0.66) | STSHSD17B1ESR1MAPTESR2 | |
| SCHEMBL12888962 | 0.88 | ESR1 (0.66) | STSHSD17B1ESR1MAPTESR2 | |
| SCHEMBL1236351 | 0.88 | ESR1 (0.66) | STSHSD17B1ESR1MAPTESR2 | |
| SCHEMBL6832890 | 0.85 | CA1 (0.52) | CA1CA2CA5ACA9STS | |
| SCHEMBL16138591 | 0.83 | CA1 (0.53) | CA1CA2CA5ACA9STS | |
| SCHEMBL11781483 | 0.82 | ESR1 (0.67) | STSHSD17B1ESR1MAPTESR2 | |
| SCHEMBL11781477 | 0.82 | ESR1 (0.67) | STSHSD17B1ESR1MAPTESR2 | |
| SCHEMBL1234800 | 0.82 | HSD17B1 (0.72) | STSHSD17B1ESR1ESR2CYP19A1 | |
| SCHEMBL12888948 | 0.82 | HSD17B1 (0.72) | STSHSD17B1ESR1ESR2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747018-B2 | TREATMENT OF ESTROGEN-DEPENDENT DISORDERS; PREFERRED COMPOUNDS HAVE 1,3,5-ESTRATRIENE NUCLEUS, AND ARE SUBSTITUTED AT C-17 OR C-11 WITH MOLECULAR MOIETY WHICH RENDERS COMPOUNDS EFFECTIVE TO BLOCK BINDING OF ESTROGEN TO ITS RECEPTOR | SRI INTERNATIONAL | 2004-06-08 | — | — | US | disclosed |
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | TANABE MASATO (US) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153543-A1 | Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use | HSD17B11, ESR2, ESRRA | CA1 2501/4885CA2 3138/4885CA5A 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.